-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, Arkema announced its 2019 full-year financial report.
The announcement stated that Arkema achieved a high level of financial performance in 2019 with the help of the special products business
.
The key data of Arkema's 2019 financial report are as follows:
⦁ Sales amounted to EUR 8.
7 billion, close to last year’s level (EUR 8.
8 billion);
⦁ Earnings before interest, tax, depreciation and amortization (EBITDA) amounted to 1.
457 billion euros, comparable to the record level in 2018 (down 1.
2%); EBITDA margin was 16.
7%;
⦁ Fourth-quarter EBITDA increased 3% year-on-year to EUR 295 million;
⦁ Adjusted net income of EUR 625 million, corresponding to a value of EUR 8.
20 per share;
⦁ Strong growth in free cash flow to EUR 667 million and an excellent EBITDA to cash conversion rate of 52% (38% in 2018);
⦁ Managed level of net debt (excluding hybrid bonds) at EUR 1.
6 billion, 1.
1 times 2019 earnings before interest, tax, depreciation and amortization (EBITDA);
⦁ The proposed dividend increases by a further 8% to EUR 2.
70 per share, reflecting the strong potential of the company's long-term strategy and its strong confidence
.
Thierry Le Hénaff, Chairman and Chief Executive Officer of Arkema Group, highlighted the following points in this financial report:
“After a record 2018, we experienced a more difficult economic climate in 2019, manifested by downturns in certain markets, such as the automotive and electronics industries, and a general lack of visibility
.
In addition to delivering a very solid financial performance, the Group continues to implement its strategy to strengthen its specialty products (1) business through high-quality reinforcement acquisitions and capacity enhancements for high value-added products, while strengthening its innovation efforts in high-performance materials
.
Outlook 2020
Outlook 2020In 2020, with the economic environment expected to remain volatile, Arkema aims to achieve earnings before interest, taxes, depreciation and amortization (EBITDA) comparable to 2019 levels, excluding the impact of the Covid-19 pandemic
.
For the full year 2020, the Group's performance will be driven by a roughly 10% increase in Bostik's EBITDA, while advanced materials remain broadly stable and the fluorine gas business declines
.